The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma

Inclusion Criteria: 1. 18 years to 70 years, expected survival \> 3 months; 2. CD19 positive B-cell lymphoma; 3. KPS \>80; 4. Having at least one measurable lesions; 5. Cardiac function: 1-2 levels; Liver: TBIL≤3ULN，AST ≤2.5ULN，ALT ≤2.5ULN; kidney: Cr≤1.25ULN; bone marrow: WBC ≥ 3.0×109/L, Hb ≥90 g/L, PLT ≥ 80×109/L）; 6. No serious allergic constitution; 7. No other serous diseases that conflicts with the clinical program; 8. No other cancer history; 9. No serious mental disorder; 10. Informed consent is signed by a subject or his lineal relation. Exclusion Criteria: 1. Pregnant or lactating women; (female participants of reproductive potential must have a negative serum or urine pregnancy test); 2. Uncontrolled active infection, HIV infection, syphilis serology reaction positive; 3. Active hepatitis B or hepatitis C infection; 4. Recent or current use of glucocorticoid or other immunosuppressor; 5. With severe cardiac, liver, renal insufficiency, diabetes and other diseases; 6. Transaminase \>2.5ULN, Bilirubin \>3ULN，Creatinine\>1.25ULN 7. Participate in other clinical research in the past three months; previously treatment with any gene therapy products; 8. Researchers think of that does not fit to participate in the study, or other cases that affect the clinical trial results;